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Innovation, whether related to drugs, vaccines, or evenprogram design, can allow services to be provided in a timely
and efﬁcient manner and to be appealing to beneﬁciaries.
Examples such as point-of-care CD4 cell counts, rapid malaria
diagnostic tests, tuberculosis diagnosis by cartridge-based
nucleic acid ampliﬁcation test, rapid HIV test kits (and more
recently HIV self-testing), and ﬁxed-dose combination anti-
retroviral therapy innovations in HIV treatment and prevention
improve the efﬁciency and reach of services. Choice is also an
important factor in acceptability and uptake of health services,
as seen in contraceptive programs where an increased
number of options are associated with increased contraceptive
uptake.1 A recent example of an innovation with potential
impact is medical devices developed for adolescent and
adult voluntary medical male circumcision (VMMC) HIV
prevention programs.
VMMC progress in the 14 priority countries of
southern and East Africa is an impressive public health
HIV prevention effort. By the end of 2015, 10 million males
had been provided with medical circumcision by HIV
prevention programs, the vast majority also receiving HIV
testing, many for the ﬁrst time.2 Additionally, VMMC was
one of 19 global health priorities referred to by the
Copenhagen Consensus Centre as a ‘best-buy’ to reach the
sustainable development goals.3 Beyond the prevention of
HIV infection, added beneﬁts of VMMC include prevention
of other sexually transmitted infections such as herpes
simplex virus and human papillomavirus infections.4,5 Not
to be forgotten is the fact that an uninfected partner is the
best protection against the sexual transmission of HIV, and
therefore, the HIV prevention beneﬁciaries of male circum-
cision include women and also men. A model for Zambia
predicts that reaching a goal of 80% circumcision among
males of 15–49 years would reduce HIV incidence among
females as much as 26% in the long term.6 Models predict
that in some countries, almost half of HIV infections averted
within a generation’s time of VMMC scale-up will be
among women.7
Achieving VMMC coverage of priority populations is
not without challenges and complexities, including cultural
barriers, establishment of new supply chains, need for high-
quality services, creation of demand for services, funding, and
need for efﬁciencies for service delivery.8 Given the goal of
VMMC scale-up at a time of decreasing resources for primary
prevention modalities, strategies and innovations are needed
to improve accessibility, increase uptake of services, ensure
sustainability, and improve cost efﬁciencies, all while main-
taining public trust and safety of the program. In contrast to
conventional surgical methods, medical devices for circum-
cision of adults and adolescent males are an innovation that
may alleviate some scale-up challenges through the elimina-
tion of complexities inherent to surgery, including the need
for sutures and injected anesthesia. Device-based techniques
are typically shorter, easier to learn, simpler to perform, and
have been safely conducted by nurses. Devices have thus
been promoted as a means to extend the reach of programs,
reduce costs, and potentially increase demand and program
efﬁciency, while maintaining or even improving on safety.9
Advantages need to be weighed against the requirement that
clients return 7 days after device placement for removal,
whereas follow-up after surgical VMMC is voluntary. Two
medical devices for adolescent and adult VMMC, PrePex and
ShangRing, have been prequaliﬁed by World Health Organi-
zation (WHO) and can be used in VMMC programs
supported by the President’s Emergency Plan for AIDS
Relief (PEPFAR) and the Global Fund for AIDS, Tubercu-
losis and Malaria.10
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Initial research on devices demonstrated safety and
acceptability in the setting of clinical trials.11,12 Despite
this, additional questions that cannot be answered in the
clinical trial setting remain, including requirements and
timelines for in-country regulatory processes, safety with
use in routine service delivery settings (including at ﬁxed,
outreach, and mobile service delivery sites), strategies for
integration of devices into ongoing programs, client
demand, impact on program reach, and the cost of
services. To further explore these issues, the Bill &
Melinda Gates Foundation and PEPFAR developed a sys-
tematic research agenda, independent from device manu-
facturers, to understand the potential of devices to
accelerate VMMC scale-up. As part of the evaluation
agenda, it was also important that questions be addressed
in contexts as close as possible to “real-life”
scaled programs.
This collection of 16 articles examines research on
the introduction of the 2 devices prequaliﬁed by WHO,
PrePex, and ShangRing. These studies provide a ﬁrm body
of evidence to inform development of recommendations
regarding device introduction into VMMC programs
already operating at scale. We offer a brief description of
the ﬁndings on introduction, including on safety, supply,
demand, and cost of VMMC using devices, as summarized
in Figure 1.
SAFETY
Given that VMMC is an elective prevention inter-
vention, comprised of a medical procedure with a perma-
nent outcome performed on young, healthy persons, safety
is of paramount importance. Hence, WHO undertakes
prequaliﬁcation to assure the safety and quality of devices
to be used in public health programs in low-resource
countries that may have weak, limited, or no regulatory
oversight of any medical devices by national authorities.
The approach taken by WHO to prequalify devices for
adolescent and adult VMMC, and also a framework for
expanding their use with postmarketing surveillance, is
described. In addition to the prequaliﬁcation steps, the
entire VMMC device clinical safety evaluation pathway
suggested by WHO is outlined, including a circumcision
device classiﬁcation scheme.13 This work continues to
serve as an important foundation to the introduction of
VMMC devices.
Other articles in this collection present numerous
lessons learned, totaling a bounty of good news (Box 1).
Introduction studies of PrePex in adults in Malawi,
Zambia, Zimbabwe, Mozambique, South Africa, and
Botswana conﬁrm that the device is safe, including in
the context of routine service delivery by nurses, and that
clients are satisﬁed and would recommend it to their
peers.14–19 A study of PrePex in Zimbabwean adolescents
aged 13–17 years provides the ﬁrst safety data in this
important younger age group, constituting the largest
number of clients who have sought VMMC services thus
far.20 Although a greater proportion of adolescents versus
adults are anatomically ineligible for PrePex, adverse
event rates, perceptions of pain, and healing time are all
less than observed using PrePex in adults.20 Providers
quickly become proﬁcient with the use of devices, and adverse
event rates with ShangRing are no different with newly trained
compared to experienced providers.21 A study comparing the
safety of using all available Shang-Ring sizes to using fewer
sizes shows both schemes to be safe.22 This type of operational
study could translate into supply chain efﬁciencies for this
device. Good outcomes are also seen with delivery of services
in mobile units, which will allow programs to extend reach to
more remote areas.23,24
FIGURE 1. Framework for systemat-
ically assessing the role of devices in
accelerating the scale-up and
improving the efficiency of the
VMMC program. COGS, cost of
goods sold; HR, human resources;
OR, operational research.
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BOX 1. Scope of supplement and lessons learned from
studies included in this supplement
Scope:
This supplement contains 16 articles from 8 coun-
tries examining different aspects of the introduction of
devices into VMMC and focus on the following:
• Safety and acceptability of device introduction in
Botswana, South Africa, Malawi, Zambia, Zimbabwe,
Mozambique, and Kenya14–20,22–24
• The WHO-deﬁned pathway for the evaluation of devices
for VMMC programs for HIV prevention13
• Estimated unit costs of device-based VMMC and cost of
device introduction27,28
• Impact of devices on demand for VMMC services26
• Provider training and client education.21,25
Lessons learned:
• Devices are safe and acceptable in routine service delivery
• In the setting of limited capacity for national regulatory
oversight, international partners needed to work with
WHO to establish a process for assurance of device
safety and quality
• Initial implementation of devices has failed to demon-
strate potential advantages with regard to efﬁciency
and cost
• Introduction will require planning and ongoing review
of operational procedures to resolve challenges that
arise
• As greater experience with devices is gained, risk factors
for adverse events and delayed healing may be identi-
ﬁed, along with risk mitigation, allowing tailored
messaging to at-risk clients
• In settings with health care worker shortages, urgent
referral of clients in need to skilled surgeons within 6–12
hours may not be possible
• A forecasting study shows that in the context of wide-
scale awareness and availability of circumcision serv-
ices, the PrePex device has potential to improve
incremental demand for VMMC
• With regard to the PrePex device:
• Safety in adolescents has been demonstrated but
many adolescents are ineligible
• Removal pain is experienced by nearly all clients;
better control and education about pain is needed
• Odor is experienced by most clients while the
device is in place; expectation setting about this
outcome is needed
• With regard to the ShangRing device:
• Men’s understanding and retention of abstinence
counseling are good and retained during the
healing period
• Performance of newly trained providers is equal to
that of experienced providers
• Use of a fewer number of sizes is safe and
acceptable and could ease supply chain logistics.
There are some important cautionary notes as well. Even
severe adverse events nearly always resolve without long-term
sequelae; however, in settings where skilled surgeons are mostly
located in urban centers, referral of clients who require surgical
management of device-related complications within the recom-
mended time frame of 6–12 hours may not be possible.18
Although PrePex is safe in adolescents, immature anatomy
precludes use in a signiﬁcant proportion of these younger clients,
and other methods will be needed.20 Reports of the nearly
universal experience of pain at the time of PrePex removal and
the development of odor while the device is in place present
potential barriers to uptake and point to the need for better pain
control with the use of this device and for appropriate client
expectation setting concerning odor.14–17,19 In response to these
ﬁndings, studies to optimize pain and odor control are ongoing.
SUPPLY AND DEMAND
Evaluation of data and operational ﬁndings regularly
present opportunities for program improvement. During deliv-
ery of mobile services in South Africa, periodic assessments
allowed improvements in logistics and service delivery.24
Analysis of clinical data from ﬁxed and outreach VMMC sites
in Kenya permitted identiﬁcation of risk factors for delayed
healing with the potential for delivery of targeted messages for
at-risk clients.22 Studies on healing with both devices reveal
that men retain abstinence messages; study ﬁndings can be
used to strengthen counseling messages to ensure adherence to
instructions and avoidance of complications, such as device
displacement/slippage.17,25 The impact of devices on demand is
analyzed using a market research–based approach to determine
the population segments where increases in uptake resulting
from introducing device options may be most likely to occur.
Data from Zimbabwe and Zambia predict a preference for the
PrePex device and substantial incremental demand.26
COST
The 2 PrePex costing studies reveal that the device itself
makes up a large part of the procedure unit cost. In modeling
studies and simulated analyses, devices have yet to show
a signiﬁcant cost advantage compared with surgery. A costing
exercise from Mozambique shows that surgery with reusable
instruments is signiﬁcantly less costly than use of PrePex at
current device unit costs, and achievement of cost savings with
devices may require novel delivery models.27 As the model from
Zambia points out, there are costs associated with devices in
addition to the basic circumcision unit costs that include training,
introduction, and product registration.28 Elsewhere, it has been
highlighted that low demand and underutilization of VMMC
services are the largest drivers of high unit costs.29 Although
market research–based methods forecast increased demand
because of availability of devices, the actual effect on demand,
and in turn costs, in real-world settings is yet to be seen.
CONCLUSIONS
This collection of articles presents new research that
underscores the challenges and opportunities for the use of
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medical devices in VMMC programs, as an alternative to
conventional surgical approaches. Findings highlighted in this
supplement will be important as the introduction of VMMC
devices continues. Key questions posed by decision makers—
will the innovation be more attractive than the existing
options, extend the reach of programs, be more cost effective,
be as safe as the current standard of care?—are not answered
simultaneously. As demonstrated through these articles,
answers are revealed across a series of activities, building
step-wise on results from previous work. Solutions to some of
the most critical questions are not knowable until substantial
investments of time, effort, and money have been committed.
For example, real-world acceptability may not be fully known
until new innovations or products are truly widely available
as a routine service option. Likewise, the most consequential
adverse events may be exceptionally rare and not appreciated
until after large numbers of clients have been reached.
Readers are encouraged to consider nuanced aspects of
product introduction, including applicability for speciﬁc
populations and settings, potential program efﬁciencies, and
possible impact on male circumcision unit costs.
Information presented here covers some of the
operational aspects of device introduction. The need for
pilot studies, objective data on safety, examination of
acceptability and costs, and documentation of the chal-
lenges encountered is not unique to this innovation. We
hope that this example can serve as a case study for the
introduction of other health products for large scale HIV
prevention and treatment.
REFERENCES
1. Systematic Review of Contraceptive Medicines “Does Choice Make
a Difference?” Available at: http://archives.who.int/eml/expcom/
expcom15/applications/sections/ContraChoiceReview.pdf. Accessed January
16, 2016.
2. 10 Million Men Stepped Up for HIV Prevention. Available at: https://www.
malecircumcision.org/resource/10-million-men-stepped-hiv-prevention.
Accessed January 16, 2016.
3. Geldsetzer P, Bloom D, Humair S, Bärnighausen T. HIV/AIDS
Perspective Paper, March 2015 PGDA Working Paper No. 123.
Available at: http://www.hsph.harvard.edu/pgda/working/. Accessed
March 19, 2016.
4. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the
prevention of HSV-2 and HPV infections and syphilis. N Engl J Med.
2009;360:1298–1309.
5. Wawer MJ, Tobian AA, Kigozi G, et al. Effect of circumcision of HIV-
negative men on transmission of human papillomavirus to HIV-
negative women: a randomised trial in Rakai, Uganda. Lancet. 2011;
377:209–218.
6. Awad SF, Sgaier SK, Tambatamba BC, et al. Investigating voluntary
medical male circumcision program efﬁciency gains through subpopu-
lation prioritization: insights from application to Zambia. PLoS One.
2015;10:e0145729.
7. Njeuhmeli E, Forsythe S, Reed J, et al. Voluntary medical male
circumcision: modeling the impact and cost of expanding male
circumcision for HIV prevention in eastern and southern Africa. PLoS
Med. 2011;8:e1001132.
8. Sgaier SK, Reed JB, Thomas A, et al. Achieving the HIV prevention
impact of voluntary medical male circumcision: lessons and challenges
for managing programs. PLoS Med. 2014;11:e1001641.
9. WHO. Guideline on the Use of Devices for Adult Male Circumcision for
HIV Prevention. Geneva, Switzerland: WHO; 2013.
10. WHO Prequaliﬁcation of Male Circumcision Devices. Available at:
http://www.who.int/diagnostics_laboratory/evaluations/prequaliﬁcation_
male_circumcision_devices/en/. Accessed January 16, 2016.
11. Mutabazi V, Kaplan SA, Rwamasirabo E, et al. HIV prevention: male
circumcision comparison between a nonsurgical device to a surgical
technique in resource-limited settings: a prospective, randomized, non-
masked trial. J Acquir Immune Deﬁc Syndr. 2012;61:49–55.
12. Sokal DC, Li PS, Zulu R, et al. Randomized controlled trial of the
shang ring versus conventional surgical techniques for adult male
circumcision: safety and acceptability. J Acquir Immune Deﬁc Syndr.
2014;65:447–455.
13. Samuelson J, Hargreave T, Ridzon R, et al. Innovative methods of male
circumcision for HIV prevention—getting the right evidence. J Acquir
Immune Deﬁc Syndr. 2016;72(suppl1):S5–S12.
14. Musiige AM, Ashengo TA, Stolarsky G, et al. Participant experiences
and views of odor and PrePex device removal pain in a VMMC
pilot study in Botswana. J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):
S73–S77.
15. Cummings B, Necochea E, Ferreira T, et al. Acceptability and
satisfaction associated with the introduction of the PrePex circumcision
device in Maputo, Mozambique. J Acquir Immune Deﬁc Syndr. 2016;
72(suppl1):S56–S62.
16. Mavhu W, Hatzold K, Ncubu G, et al. Safety and acceptability of the
PrePex device when used in routine male circumcision service delivery
during active surveillance in Zimbabwe. J Acquir Immune Deﬁc Syndr.
2016;72(suppl1):S63–S68.
17. Feldblum P, Martinson N, Bvulani B, et al. Safety and efﬁcacy of the
PrePex male circumcision device: results from pilot implementation
studies in Mozambique, South Africa, and Zambia. J Acquir Immune
Deﬁc Syndr. 2016;72(suppl1):S43–S48.
18. Kohler PK, Tippett Barr BA, Kang’ombe A, et al. Safety, feasibility, and
acceptability of the PrePex device for adult male circumcision in Malawi.
J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):S49–S55.
19. Milovanovic M, Taruberekera N, Martinson N, et al. Perceptions of the
PrePex device among men who received or refused PrePex circumcision
and people accompanying them. J Acquir Immune Deﬁc Syndr. 2016;
72(suppl1):S78–S82.
20. Tshimanga M, Hatzold K, Mugurungi O, et al. Safety proﬁle of PrePex
male circumcision device and client satisfaction with adolescents males
aged 13-17 years in Zimbabwe. J Acquir Immune Deﬁc Syndr. 2016;
72(suppl1):S36–S42.
21. Awori QD, Lee RK, Li PS, et al. Surgical outcomes of newly trained
ShangRing circumcision providers. J Acquir Immune Deﬁc Syndr. 2016;
72(suppl1):S13–S17.
22. Feldblum PJ, Odoyo-June E, Bailey RC, et al. Factors associated with
delayed healing in a study of the PrePex device for adult male
circumcision in Kenya. J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):
S24–S29.
23. Feldblum PJ, Zulu R, Linyama D, et al. Randomized controlled trial of
the ShangRing for adult medical male circumcision: safety, effectiveness,
and acceptability of using 7 versus 14 device sizes. J Acquir Immune
Deﬁc Syndr. 2016;72(suppl1):S30–S35.
24. Kufa T, Chetty-Makkan C, Maraisane M, et al. Delivering PrePex
medical male circumcision services through a mobile clinic: the
experience from a pilot project in North West Province, South Africa.
J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):S69–S72.
25. Barone MA, Li PS, Zulu R, et al. Men’s understanding of and
experiences during the Post-circumcision abstinence period: results from
a ﬁeld study of ShangRing circumcision during routine clinical services
in Kenya and Zambia. J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):
S18–S23.
26. Fram F, Church F, Sundaram M, et al. Employing demand-based
volumetric forecasting to identify potential for and roles of devices in
scale-up of medical male circumcision in Zambia and Zimbabwe.
J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):S83–S89.
27. Schutte C, Tshimanga M, Mugurungi O, et al. Comparative cost analysis
of surgical and PrePex device male circumcision in Zimbabwe and
Mozambique. J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):S96–S100.
28. Vandament L, Chintu N, Yano N, et al. Evaluating opportunities for
achieving cost efﬁciencies through the introduction of PrePex device
male circumcision in adult VMMC programs in Zambia and Zimbabwe.
J Acquir Immune Deﬁc Syndr. 2016;72(suppl1):S90–S95.
29. Bollinger L, Adesina A, Forsythe S, et al. Cost drivers for voluntary
medical male circumcision using primary source data from sub-Saharan
Africa. PLoS One. 2014;9:e84701.
Ridzon et al J Acquir Immune Defic Syndr  Volume 72, Supplement 1, June 1, 2016
S4 | www.jaids.com Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
